In order for our site to display correctly you will need a newer version of your web browser.

Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.

Related Topics

The Bone Marrow Transplant and Cellular Therapy Process

The mission of the St. Jude Transplant Program is to provide excellent patient care for children, adolescents and young adults with disorders curable by bone marrow transplant or cellular therapy, and to advance clinical transplantation research. All patients who undergo transplants or cellular therapy at our institution are treated on research protocols.

The types of stem cell / bone marrow transplants performed at St. Jude include autologous and allogeneic transplantation. In autologous transplants, patients receive their own hematopoietic stem cells that have been harvested earlier. Autologous transplant is typically used for patients who have solid tumors or lymphomas that are at high risk of treatment failure. These solid tumors include neuroblastoma, Ewing sarcoma/primitive neuroectodermal tumor (PNET), rhabdomyosarcoma, brain tumors, germ cell tumors, Wilms tumors; non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma. In allogeneic stem cell / bone marrow transplants, the patients receive hematopoietic stem cells from other persons.

St. Jude is conducting pivotal clinical trials in cellular therapy for leukemia that fails to respond to chemotherapy. Patients receive natural killer (NK) cells donated by their parents. NK cells transplants are performed alone or in combination with bone marrow transplants. Novel NK cell typing techniques are used to select the best NK cell donor. Gene modifications and cell processing research is being conducted to increase the potency of donor NK cells to improve the chance of cure for high risk childhood leukemia.